-
公开(公告)号:US08168590B2
公开(公告)日:2012-05-01
申请号:US12349531
申请日:2009-01-07
申请人: Sabine Eming , Thomas Krieg , Stephan Sollberg , Gereon Lauer
发明人: Sabine Eming , Thomas Krieg , Stephan Sollberg , Gereon Lauer
IPC分类号: A61K38/18 , C07K14/475
CPC分类号: C07K14/52 , A61K38/1866
摘要: The invention relates to vascular endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
摘要翻译: 本发明涉及其中AA位置111处的丙氨酸被脯氨酸替代的血管内皮生长因子(VEGF)。 AA位置110处的精氨酸可另外被另一氨基酸替代。 本发明还涉及根据本发明的VEGF的衍生物,核酸,表达系统,药物以及本发明的VEGF突变体用于治疗慢性伤口的用途。
-
公开(公告)号:US20060148687A1
公开(公告)日:2006-07-06
申请号:US10506893
申请日:2003-03-06
申请人: Sabine Eming , Thomas Krieg , Stephan Sollberg , Gereon Lauer
发明人: Sabine Eming , Thomas Krieg , Stephan Sollberg , Gereon Lauer
IPC分类号: A61K38/18 , C07K14/475
CPC分类号: C07K14/52 , A61K38/1866
摘要: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
摘要翻译: 本发明涉及其中AA位置111处的丙氨酸被脯氨酸替代的内皮生长因子(VEGF)。 AA位置110处的精氨酸可另外被另一氨基酸替代。 本发明还涉及根据本发明的VEGF的衍生物,核酸,表达系统,药物以及本发明的VEGF突变体用于治疗慢性伤口的用途。
-
公开(公告)号:US20120258915A1
公开(公告)日:2012-10-11
申请号:US13445016
申请日:2012-04-12
申请人: Sabine Eming , Thomas Krieg , Stephan Sollberg , Gereon Lauer
发明人: Sabine Eming , Thomas Krieg , Stephan Sollberg , Gereon Lauer
CPC分类号: C07K14/52 , A61K38/1866
摘要: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
摘要翻译: 本发明涉及其中AA位置111处的丙氨酸被脯氨酸替代的内皮生长因子(VEGF)。 AA位置110处的精氨酸可另外被另一氨基酸替代。 本发明还涉及根据本发明的VEGF的衍生物,核酸,表达系统,药物以及本发明的VEGF突变体用于治疗慢性伤口的用途。
-
公开(公告)号:US20110009316A1
公开(公告)日:2011-01-13
申请号:US12349531
申请日:2009-01-07
申请人: Sabine EMING , Thomas KRIEG , Stephan SOLLBERG , Gereon LAUER
发明人: Sabine EMING , Thomas KRIEG , Stephan SOLLBERG , Gereon LAUER
IPC分类号: A61K38/18 , A61P7/06 , A61P29/00 , A61P35/00 , A61P7/00 , A61P17/00 , A61P3/00 , A61P7/10 , A61P9/00 , A61P3/10 , A61P19/06 , A61P1/04 , A61P35/04
CPC分类号: C07K14/52 , A61K38/1866
摘要: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
摘要翻译: 本发明涉及内皮生长因子(VEGF),其中AA位置111处的丙氨酸被脯氨酸替代。 AA位置110处的精氨酸可另外被另一氨基酸替代。 本发明还涉及根据本发明的VEGF的衍生物,核酸,表达系统,药物以及本发明的VEGF突变体用于治疗慢性伤口的用途。
-
公开(公告)号:US07491696B2
公开(公告)日:2009-02-17
申请号:US10506893
申请日:2003-03-06
申请人: Sabine Eming , Thomas Krieg , Stephan Sollberg , Gereon Lauer
发明人: Sabine Eming , Thomas Krieg , Stephan Sollberg , Gereon Lauer
IPC分类号: A61K38/18 , C07K14/475 , C12N15/18 , C12N15/63
CPC分类号: C07K14/52 , A61K38/1866
摘要: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
摘要翻译: 本发明涉及其中AA位置111处的丙氨酸被脯氨酸替代的内皮生长因子(VEGF)。 AA位置110处的精氨酸可另外被另一氨基酸替代。 本发明还涉及根据本发明的VEGF的衍生物,核酸,表达系统,药物以及本发明的VEGF突变体用于治疗慢性伤口的用途。
-
-
-
-